留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

烟碱乙酰胆碱受体作为镇痛靶点的研究进展

诸德源 王一然 蔡国君 徐添颖

诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
引用本文: 诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
Citation: ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005

烟碱乙酰胆碱受体作为镇痛靶点的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.005
基金项目: 国家自然科学基金青年科学基金项目(81102487);国家科技重大专项"重大新药创制"(2009ZX09303-002);第二军医大学教学改革重点项目(临床医学8年制课程整合-心血管系统,BMB2014016)

Advance in nicotinic acetylcholine receptors as analgesic targets

  • 摘要: 烟碱乙酰胆碱受体(nicotinic acetylcholine receptors, nAChRs)亦称神经型尼古丁受体,在中枢和外周神经系统有广泛表达。该类受体在疼痛的信号调节中发挥重要作用。近几年,人们发现以nAChRs不同亚单位作为靶点的激动剂在多种急性和慢性疼痛模型上显示良好效果,对于发展新型低成瘾性的镇痛药物具有重要的指导意义。nAChRs阳性变构调节剂为进一步提高该类药物的镇痛效能和拓展治疗窗提供了新思路。综述近几年nAChRs与镇痛研究的最新进展,并分析该领域未来的研究热点。
  • [1] Del Bufalo A, Cesario A, Salinaro G, et al. Alpha9 alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain [J]. Curr Pharm Des, 2014, 20(38): 6042-6047.
    [2] Woodcock J. A difficult balance——pain management, drug safety, and the FDA [J]. N Engl J Med, 2009, 361(22): 2105-2107.
    [3] Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence [J]. Clin J Pain, 2008, 24(6): 469-478.
    [4] Smith HS. Opioids and neuropathic pain [J]. Pain Physician, 2012, 15(3 Suppl): ES93-110.
    [5] Corti C. A history of smoking [M]. Montana: Kessinger Publishing, 2007:112.
    [6] Davis L, Pollock LJ, Stone T. Visceral pain [J]. Surg Gynecol Obstetr, 1932, 55: 418-427.
    [7] Sahley TL, Berntson GG. Antinociceptive effects of central and systemic administrations of nicotine in the rat [J]. Psychopharmacology, 1979, 65(3):279-283.
    [8] Garraffo HM, Spande TF, Williams M. Epibatidine: from frog alkaloid to analgesic clinical candidates. A testimonial to true grit! [J]. Heterocycles, 2009, 79: 207-217.
    [9] Rupniak NM, Patel S, Marwood R, et al. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributableto nicotinic agonist activity [J]. Br J Pharmacol, 1994, 113(4): 1487-1493.
    [10] Umana IC, Daniele CA, McGehee DS. Neuronal nicotinic receptors as analgesic targets: it's a winding road [J]. Biochem Pharmacol, 2013, 86(8): 1208-1214.
    [11] Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits [J]. Nature, 1999, 398(6730): 805-810.
    [12] Nirogi R, Goura V, Abraham R, et al. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain [J]. Eur J Pharmacol, 2013, 712(1-3): 22-29.
    [13] Rueter LE, Meyer MD, Decker MW. Spinal mechanisms underlying A-85380-induced effects on acute thermal pain [J]. Brain Res, 2000, 872(1-2): 93-101.
    [14] Daly JW, Garraffo HM, Spande TF, et al. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics [J]. Nat Prod Rep, 2000, 17(2): 131-135.
    [15] Bannon AW, Decker MW, Holladay MW, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors[J]. Science, 1998, 279(5347): 77-81.
    [16] Lynch JJ 3rd, Wade CL, Mikusa JP, et al. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model [J].Eur J Pharmacol, 2005, 509(1): 43-48.
    [17] Holladay MW, Wasicak JT, Lin NH, et al. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors [J]. J Med Chem, 1998, 41(4): 407-412.
    [18] Alsharari SD, Freitas K, Damaj MI. Functional role of alpha7 nicotinic receptor in chronic neuropathic and inflammatory pain: studies in transgenic mice [J]. Biochem Pharmacol, 2013, 86(8):1201-1207.
    [19] Gao B, Hierl M, Clarkin K, et al. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptoragonists in animal models of persistent pain [J]. Pain,2010, 149(1): 33-49.
    [20] Bagdas D, Sonat FA, Hamurtekin E, et al. The antihyperalgesic effect of cytidine-50-diphosphate-choline in neuropathic and inflammatory pain models [J]. Behav Pharmacol, 2011, 22(5-6): 589-598.
    [21] 刘献文, 张宗旺. 尼古丁镇痛作用机制的研究进展 [J]. 国际麻醉学与复苏杂志, 2013, 34(4): 368-370.
    [22] Cordero-Erausquin M, Changeux JP. Tonic nicotinic modulation of serotoninergic transmission in the spinal cord [J]. Proc Natl Acad Sci(USA), 2001, 98(5): 2803-2807.
    [23] Frber L, Stratz T, Brückle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group [J]. Scand J Rheumatol Suppl, 2000, 113: 49-54.
    [24] Ramirez-Latorre J, Yu CR, Qu X, et al. Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels [J]. Nature,1996, 380(6572): 347-351.
    [25] Jackson KJ, Sanjakdar SS, Muldoon PP, et al. a3b4*nicotinic acetylcholine receptor subtype mediates nicotine reward and physicalnicotine withdrawal signs independently of the a5 subunit in the mouse[J]. Neuropharmacology, 2013, 70: 228-235.
    [26] Lee CH, Zhu C, Malysz J, et al. a4b2neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of a4b2 nAChR agonists in pain [J]. Biochem Pharmacol, 2011, 82(8):959-966.
    [27] Uteshev VV. The therapeutic promise of positive allosteric modulation of nicotinic receptors [J]. Eur J Pharmacol, 2014, 727: 181-185.
    [28] Zhu CZ, Chin CL, Rustay NR, et al. Potentiation ofanalgesic efficacy but not side effects: co-administration of an alpha4beta2neuronal nicotinic acetylcholine receptor agonist and its positive allostericmodulator in experimental models of pain in rats [J]. Biochem Pharmacol, 2011, 82(8): 967-976.
    [29] Freitas K, Negus SS, Carroll FI, et al. In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model [J]. Br J Pharmacol, 2013, 169(3): 567-579.
  • [1] 董发慧, 韩金刚.  地塞米松联合右美托咪定对罗哌卡因股神经阻滞用于老年患者全膝关节置换术后镇痛效果的评价 . 药学实践与服务, 2023, 41(2): 125-129. doi: 10.12206/j.issn.2097-2024.202109020
    [2] 张慧敏, 向科发, 史小飞, 秦臻, 刘霞.  胆碱能抗炎通路α7烟碱型乙酰胆碱受体的最新研究进展 . 药学实践与服务, 2022, 40(6): 485-493. doi: 10.12206/j.issn.2097-2024.202204037
    [3] 徐熠, 刘静, 黄瑾, 崔金刚, 吴铁军.  痛风颗粒各有效部位群对关节炎大鼠的抗炎镇痛作用研究 . 药学实践与服务, 2020, 38(6): 528-532. doi: 10.12206/j.issn.1006-0111.202007015
    [4] 唐焕君.  ACEI联合醛固酮受体拮抗剂对高血压肾病患者Cys-C及尿微量蛋白的调节作用 . 药学实践与服务, 2018, 36(2): 131-135. doi: 10.3969/j.issn.1006-0111.2018.02.008
    [5] 黄晓冰, 吴雪茹, 吴涵, 谢华民.  新工艺温通膏主要药效学研究 . 药学实践与服务, 2018, 36(6): 507-511. doi: 10.3969/j.issn.1006-0111.2018.06.007
    [6] 施赛健, 张文, 厉廷有, 庄春林.  抗肿瘤多药耐药微管蛋白调节剂的研究进展 . 药学实践与服务, 2017, 35(5): 385-393,397. doi: 10.3969/j.issn.1006-0111.2017.05.001
    [7] 林辉, 杨远, 王志红, 林川, 周伟平.  帕瑞昔布钠在肝癌肝切除术后的应用 . 药学实践与服务, 2017, 35(1): 73-74,81. doi: 10.3969/j.issn.1006-0111.2017.01.018
    [8] 丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业.  选择性雌激素受体调节剂研究现状 . 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
    [9] 刘佃花, 张恩晖, 刘冲, 范博士, 蔡国君.  烟碱致动脉粥样硬化的N胆碱受体信号通路 . 药学实践与服务, 2014, 32(2): 81-84. doi: 10.3969/j.issn.1006-0111.2014.02.001
    [10] 米丽, 陈万生, 李敬超, 吴广通.  菊黄清热散的临床前药效学研究 . 药学实践与服务, 2014, 32(3): 212-215,234. doi: 10.3969/j.issn.1006-0111.2014.03.013
    [11] 武雪宾, 虞慧华, 唐亮, 尤本明.  通脉愈伤胶囊抗炎镇痛作用的实验研究 . 药学实践与服务, 2010, 28(3): 193-195.
    [12] 陆晓芳, 李琼珍, 朱涛.  芬太尼透皮贴剂用于日间肛门手术病人的术后镇痛及安全性的临床观察 . 药学实践与服务, 2010, 28(5): 356-358.
    [13] 李晏, 陈渊源, 伊佳, 蒋红, 沈甫明.  气滞胃痛颗粒促进胃肠运动和镇痛作用研究 . 药学实践与服务, 2009, 27(2): 90-93.
    [14] 费逸明, 龚纯贵.  白英提取物镇痛抗炎作用的实验研究 . 药学实践与服务, 2009, 27(2): 111-114.
    [15] 魏显招, 田径, 陈盛新.  创伤疼痛的药物处理进展 . 药学实践与服务, 2008, (6): 401-404.
    [16] 朱昱, 韩婷, 张巧艳, 秦路平.  番红花不同药用部位的镇痛和抗炎活性比较研究 . 药学实践与服务, 2008, (4): 269-271.
    [17] 林惠卿, 蔡少甫, 杜青云.  高乌甲素用于Ⅱ度烧伤后镇痛的临床观察 . 药学实践与服务, 2007, (5): 323-324.
    [18] 龚纯贵, 张国庆, 王希营, 雷彦辉.  仙鹤草提取物镇痛抗炎试验的实验研究 . 药学实践与服务, 2006, (6): 339-341,356.
    [19] 魏文树, 张紫洞.  解热镇痛抗炎药 . 药学实践与服务, 1988, (4): 13-15.
    [20] 徐炳祥.  合成免疫调节剂的研究进展 . 药学实践与服务, 1988, (2): 7-10.
  • 加载中
计量
  • 文章访问数:  3000
  • HTML全文浏览量:  355
  • PDF下载量:  609
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-01-07
  • 修回日期:  2015-05-05

烟碱乙酰胆碱受体作为镇痛靶点的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.005
    基金项目:  国家自然科学基金青年科学基金项目(81102487);国家科技重大专项"重大新药创制"(2009ZX09303-002);第二军医大学教学改革重点项目(临床医学8年制课程整合-心血管系统,BMB2014016)

摘要: 烟碱乙酰胆碱受体(nicotinic acetylcholine receptors, nAChRs)亦称神经型尼古丁受体,在中枢和外周神经系统有广泛表达。该类受体在疼痛的信号调节中发挥重要作用。近几年,人们发现以nAChRs不同亚单位作为靶点的激动剂在多种急性和慢性疼痛模型上显示良好效果,对于发展新型低成瘾性的镇痛药物具有重要的指导意义。nAChRs阳性变构调节剂为进一步提高该类药物的镇痛效能和拓展治疗窗提供了新思路。综述近几年nAChRs与镇痛研究的最新进展,并分析该领域未来的研究热点。

English Abstract

诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
引用本文: 诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
Citation: ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
参考文献 (29)

目录

    /

    返回文章
    返回